Current Oncology Reports

, Volume 14, Issue 1, pp 48–54 | Cite as

Epidemiology of Brain Metastases

  • Lakshmi Nayak
  • Eudocia Quant Lee
  • Patrick Y. Wen
Neuro-oncology (M Gilbert, Section Editor)

Abstract

Brain metastases are one of the most common neurologic complications of cancer. The incidence is 9%–17% based on various studies, although the exact incidence is thought to be higher. The incidence is increasing with the availability of improved imaging techniques which aid early diagnosis, and effective systemic treatment regimens which prolong life, thus allowing cancer to disseminate to the brain. Lung cancer, breast cancer, and melanoma are the most frequent to develop brain metastases, and account for 67%–80% of all cancers. Most patients with brain metastases have synchronous extracerebral metastases. Some patients present with no known primary cancer diagnosis. In children, brain metastases are rare; germ cell tumors, sarcomas, and neuroblastoma are the common offenders.

Keywords

Brain metastases Intracranial Incidence Epidemiology Non–small cell lung cancer Breast cancer Melanoma 

Notes

Disclosure

L. Nayak: none; E. Q. Lee: board membership for Novartis and Genentech; P. Y. Wen: consultant to Novartis and Genzyme.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    • DeAngelis LM, Posner JB. Intracranial metastases. In: DeAngelis LM, Posner JB, editors. Neurologic complications of cancer. New York: Oxford University Press; 2009. p. 141–193. This book is the most comprehensive review of neurologic complications of cancer, including intracranial metastases.Google Scholar
  2. 2.
    Johnson JD, Young B. Demographics of brain metastasis. Neurosurg Clin N Am. 1996;7:337–44.PubMedGoogle Scholar
  3. 3.
    Barker 2nd FG. Craniotomy for the resection of metastatic brain tumors in the U.S., 1988–2000: decreasing mortality and the effect of provider caseload. Cancer. 2004;100:999–1007.PubMedCrossRefGoogle Scholar
  4. 4.
    Percy AK, Elveback LR, Okazaki H, Kurland LT. Neoplasms of the central nervous system. Epidemiologic considerations. Neurology. 1972;22:40–8.PubMedGoogle Scholar
  5. 5.
    Walker AE, Robins M, Weinfeld FD. Epidemiology of brain tumors: the national survey of intracranial neoplasms. Neurology. 1985;35:219–26.PubMedGoogle Scholar
  6. 6.
    Counsell CE, Collie DA, Grant R. Incidence of intracranial tumours in the Lothian region of Scotland, 1989–90. J Neurol Neurosurg Psychiatry. 1996;61:143–50.PubMedCrossRefGoogle Scholar
  7. 7.
    Schouten LJ, Rutten J, Huveneers HA, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer. 2002;94:2698–705.PubMedCrossRefGoogle Scholar
  8. 8.
    Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22:2865–72.PubMedCrossRefGoogle Scholar
  9. 9.
    Posner JB, Chernik NL. Intracranial metastases from systemic cancer. Adv Neurol. 1978;19:579–92.PubMedGoogle Scholar
  10. 10.
    Takakura K, Sano K, Hojo S, Hirano A. Metastatic tumors of the central nervous system. Tokyo: Igaku-Shoin; 1982.Google Scholar
  11. 11.
    Pickren JW, Lopez G, Tsukada Y, Lane WW. Brain metastases: an autopsy study. Cancer Treat Symp. 1983;2:295–313.Google Scholar
  12. 12.
    • Fabi A, Felici A, Metro G et al. Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center. J Exp Clin Cancer Res. 2011;30:10. This survey provides recent data from four Italian cancer centers on brain metastases from solid tumors.PubMedCrossRefGoogle Scholar
  13. 13.
    Clayton AJ, Danson S, Jolly S, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer. 2004;91:639–43.PubMedGoogle Scholar
  14. 14.
    Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003;97:2972–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res. 2007;13:1648–55.PubMedCrossRefGoogle Scholar
  16. 16.
    Stemmler HJ, Kahlert S, Siekiera W, et al. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast. 2006;15:219–25.PubMedCrossRefGoogle Scholar
  17. 17.
    Yau T, Swanton C, Chua S, et al. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol. 2006;45:196–201.PubMedCrossRefGoogle Scholar
  18. 18.
    Stark AM, Stohring C, Hedderich J, et al. Surgical treatment for brain metastases: Prognostic factors and survival in 309 patients with regard to patient age. J Clin Neurosci. 2011;18:34–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Nussbaum ES, Djalilian HR, Cho KH, Hall WA. Brain metastases. Histology, multiplicity, surgery, and survival. Cancer. 1996;78:1781–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Delattre JY, Krol G, Thaler HT, Posner JB. Distribution of brain metastases. Arch Neurol. 1988;45:741–4.PubMedCrossRefGoogle Scholar
  21. 21.
    Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322:494–500.PubMedCrossRefGoogle Scholar
  22. 22.
    Graf AH, Buchberger W, Langmayr H, Schmid KW. Site preference of metastatic tumours of the brain. Virchows Arch A Pathol Anat Histopathol. 1988;412:493–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Lagerwaard FJ, Levendag PC, Nowak PJ, et al. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys. 1999;43:795–803.PubMedCrossRefGoogle Scholar
  24. 24.
    Ruda R, Borgognone M, Benech F, et al. Brain metastases from unknown primary tumour: a prospective study. J Neurol. 2001;248:394–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Mavrakis AN, Halpern EF, Barker 2nd FG, et al. Diagnostic evaluation of patients with a brain mass as the presenting manifestation of cancer. Neurology. 2005;65:908–11.PubMedCrossRefGoogle Scholar
  26. 26.
    • Vuong DA, Rades D, Vo SQ, Busse R. Extracranial metastatic patterns on occurrence of brain metastases. J Neurooncol. 2011. This study evaluates a large number of patients with brain metastases and provides data on the pattern of metastases outside the brain. Google Scholar
  27. 27.
    • Hubbs JL, Boyd JA, Hollis D et al. Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer. Cancer. 2010;116:5038–5046. This is a recent retrospective review evaluating the risk factors in patients with NSCLC in the development of brain metastases.PubMedCrossRefGoogle Scholar
  28. 28.
    Shi AA, Digumarthy SR, Temel JS, et al. Does initial staging or tumor histology better identify asymptomatic brain metastases in patients with non-small cell lung cancer? J Thorac Oncol. 2006;1:205–10.PubMedGoogle Scholar
  29. 29.
    Chen AM, Jahan TM, Jablons DM, et al. Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer: clinical implications for the subsequent management of the brain. Cancer. 2007;109:1668–75.PubMedCrossRefGoogle Scholar
  30. 30.
    Hung JJ, Jeng WJ, Hsu WH, et al. Prognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis. Thorax. 2010;65:241–5.PubMedCrossRefGoogle Scholar
  31. 31.
    Tomlinson BE, Perry RH, Stewart-Wynne EG. Influence of site of origin of lung carcinomas on clinical presentation and central nervous system metastases. J Neurol Neurosurg Psychiatry. 1979;42:82–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Yawn BP, Wollan PC, Schroeder C, et al. Temporal and gender-related trends in brain metastases from lung and breast cancer. Minn Med. 2003;86:32–7.PubMedGoogle Scholar
  33. 33.
    Heon S, Yeap BY, Britt GJ, et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2010;16:5873–82.PubMedCrossRefGoogle Scholar
  34. 34.
    Seute T, Leffers P, Wilmink JT, et al. Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy. J Clin Oncol. 2006;24:2079–83.PubMedCrossRefGoogle Scholar
  35. 35.
    Greenspoon JN, Evans WK, Cai W, Wright JR. Selecting patients with extensive-stage small cell lung cancer for prophylactic cranial irradiation by predicting brain metastases. J Thorac Oncol. 2011;6:808–12.PubMedCrossRefGoogle Scholar
  36. 36.
    Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357:664–72.PubMedCrossRefGoogle Scholar
  37. 37.
    Stemmler HJ, Heinemann V. Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge. Oncologist. 2008;13:739–50.PubMedCrossRefGoogle Scholar
  38. 38.
    Pestalozzi BC, Zahrieh D, Price KN, et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol. 2006;17:935–44.PubMedCrossRefGoogle Scholar
  39. 39.
    Gonzalez-Angulo AM, Cristofanilli M, Strom EA, et al. Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment. Cancer. 2004;101:1760–6.PubMedCrossRefGoogle Scholar
  40. 40.
    Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004;22:3608–17.PubMedCrossRefGoogle Scholar
  41. 41.
    Dawood S, Broglio K, Esteva FJ, et al. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol. 2009;20:621–7.PubMedCrossRefGoogle Scholar
  42. 42.
    Anders CK, Deal AM, Miller CR, et al. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer. 2011;117:1602–11.PubMedCrossRefGoogle Scholar
  43. 43.
    Albiges L, Andre F, Balleyguier C, et al. Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases. Ann Oncol. 2005;16:1846–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Gabos Z, Sinha R, Hanson J, et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol. 2006;24:5658–63.PubMedCrossRefGoogle Scholar
  45. 45.
    • Musolino A, Ciccolallo L, Panebianco M et al. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study. Cancer. 2011;117:1837–1846. This is the first population-based study evaluating the relationship of HER2-positive patients and use of trastuzumab in the development of brain metastases. PubMedCrossRefGoogle Scholar
  46. 46.
    Leyland-Jones B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol. 2009;27:5278–86.PubMedCrossRefGoogle Scholar
  47. 47.
    Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369:29–36.PubMedCrossRefGoogle Scholar
  48. 48.
    Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84.PubMedCrossRefGoogle Scholar
  49. 49.
    • Bria E, Cuppone F, Fornier M et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat. 2008;109:231–239. This provides a review of the three major randomized phase 3 trials using trastuzumab and a meta-analysis of those trials.PubMedCrossRefGoogle Scholar
  50. 50.
    Sul J, Posner JB. Brain metastases: epidemiology and pathophysiology. Cancer Treat Res. 2007;136:1–21.PubMedCrossRefGoogle Scholar
  51. 51.
    Dasgupta T, Brasfield R. Metastatic melanoma. A clinicopathological study. Cancer. 1964;17:1323–39.PubMedCrossRefGoogle Scholar
  52. 52.
    Patel JK, Didolkar MS, Pickren JW, Moore RH. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg. 1978;135:807–10.PubMedCrossRefGoogle Scholar
  53. 53.
    de la Monte SM, Moore GW, Hutchins GM. Patterned distribution of metastases from malignant melanoma in humans. Cancer Res. 1983;43:3427–33.PubMedGoogle Scholar
  54. 54.
    Sampson JH, Carter Jr JH, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg. 1998;88:11–20.PubMedCrossRefGoogle Scholar
  55. 55.
    Zakrzewski J, Geraghty LN, Rose AE, et al. Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer. 2011;117:1711–20.PubMedCrossRefGoogle Scholar
  56. 56.
    Daryanani D, Plukker JT, de Jong MA, et al. Increased incidence of brain metastases in cutaneous head and neck melanoma. Melanoma Res. 2005;15:119–124.57.PubMedCrossRefGoogle Scholar
  57. 57.
    Raizer JJ, Hwu WJ, Panageas KS, et al. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol. 2008;10:199–207.PubMedCrossRefGoogle Scholar
  58. 58.
    Wronski M, Arbit E. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J Neurosurg. 2000;93:9–18.PubMedCrossRefGoogle Scholar
  59. 59.
    Liew DN, Kano H, Kondziolka D, et al. Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article. J Neurosurg. 2011;114:769–79.PubMedCrossRefGoogle Scholar
  60. 60.
    Miyao N, Naito S, Ozono S, et al. Late recurrence of renal cell carcinoma: retrospective and collaborative study of the Japanese Society of Renal Cancer. Urology. 2011;77:379–84.PubMedCrossRefGoogle Scholar
  61. 61.
    Wronski M, Arbit E, Russo P, Galicich JH. Surgical resection of brain metastases from renal cell carcinoma in 50 patients. Urology. 1996;47:187–93.PubMedCrossRefGoogle Scholar
  62. 62.
    Mongan JP, Fadul CE, Cole BF, et al. Brain metastases from colorectal cancer: risk factors, incidence, and the possible role of chemokines. Clin Colorectal Cancer. 2009;8:100–5.CrossRefGoogle Scholar
  63. 63.
    Kruser TJ, Chao ST, Elson P, et al. Multidisciplinary management of colorectal brain metastases: a retrospective study. Cancer. 2008;113:158–65.PubMedCrossRefGoogle Scholar
  64. 64.
    Nieder C, Pawinski A, Balteskard L. Colorectal cancer metastatic to the brain: time trends in presentation and outcome. Oncology. 2009;76:369–74.PubMedCrossRefGoogle Scholar
  65. 65.
    Giordana MT, Cordera S, Boghi A. Cerebral metastases as first symptom of cancer: a clinico-pathologic study. J Neurooncol. 2000;50:265–73.PubMedCrossRefGoogle Scholar
  66. 66.
    Bouffet E, Doumi N, Thiesse P, et al. Brain metastases in children with solid tumors. Cancer. 1997;79:403–10.PubMedCrossRefGoogle Scholar
  67. 67.
    Kebudi R, Ayan I, Gorgun O, et al. Brain metastasis in pediatric extracranial solid tumors: survey and literature review. J Neurooncol. 2005;71:43–8.PubMedCrossRefGoogle Scholar
  68. 68.
    Graus F, Walker RW, Allen JC. Brain metastases in children. J Pediatr. 1983;103:558–61.PubMedCrossRefGoogle Scholar
  69. 69.
    Curless RG, Toledano SR, Ragheb J, et al. Hematogenous brain metastasis in children. Pediatr Neurol. 2002;26:219–21.PubMedCrossRefGoogle Scholar
  70. 70.
    Kramer K, Kushner B, Heller G, Cheung NK. Neuroblastoma metastatic to the central nervous system. The Memorial Sloan-kettering Cancer Center experience and a literature review. Cancer. 2001;91:1510–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Lakshmi Nayak
    • 1
  • Eudocia Quant Lee
    • 1
  • Patrick Y. Wen
    • 1
  1. 1.Center for Neuro-Oncology, Dana-Farber/Brigham and Women’s Cancer CenterDivision of Neuro-Oncology, Department of Neurology, Brigham and Women’s HospitalBostonUSA

Personalised recommendations